Nomura Holdings’s Vaxcyte PCVX Stock Holding History

Nomura Holdings’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-148,000	Closed	-$5.33M	–	2099
2025 Q3	$5.33M	Buy	+148,000	New	+$4.9M	0.01%	748
2024 Q2	–	Sell	-45,500	Closed	-$3.11M	–	1964
2024 Q1	$3.11M	Sell	45,500 -19,500	-30%	-$1.35M	0.01%	770
2023 Q4	$4.08M	Buy	+65,000	New	+$3.38M	0.01%	733

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Nomura Holdings's PCVX Position: Q4 2024 in Review

Nomura Holdings sold out of Vaxcyte (PCVX) in Q4 2024, closing a stake of 2,681 shares — an estimated $306K sold.

Nomura Holdings first reported a position in PCVX in Q3 2024 and held it in 1 quarter. The position peaked at $306K in Q3 2024. 323 funds tracked by Wall St. Rank hold PCVX as of Q4 2024.

Nomura Holdings reported no remaining Vaxcyte position as of Q4 2024 after selling out during the quarter.
Nomura Holdings sold 2,681 Vaxcyte shares in Q4 2024, an estimated $306K.
Nomura Holdings first reported a position in Vaxcyte in Q3 2024 and held it in 1 quarter.
Nomura Holdings's Vaxcyte position peaked at $306K in Q3 2024.
323 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2024.

Based on Nomura Holdings's 13F filing for Q4 2024, filed 14 Feb 2025.